News Column

Trevena Initiates Clinical Development of TRV734, a Novel Biased Ligand for Moderate to Severe Pain

February 19, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Trevena, Inc. (NASDAQ:TRVN), a clinical-stage pharmaceutical company and leader in the discovery and development of G protein coupled receptor (GPCR) biased ligands, announced the initiation of its first Phase 1 trial for TRV734, a novel drug candidate in development as an orally administered treatment for moderate to severe acute and chronic pain. TRV734 is being developed to optimize analgesia while minimizing on-target gastrointestinal and respiratory effects through its novel biased ligand mechanism at the mu-opioid receptor. TRV734 takes advantage of the same receptor specificity mechanism as does Trevena's Phase 2 clinical candidate, TRV130, an intravenous mu-opioid G protein biased ligand being developed for acute postoperative pain (see also Pharmaceutical Companies).

"With a targeted mechanism of action giving the potential to mitigate a number of dose-limiting side effects associated with current opioid treatments, we believe TRV734 holds great promise as a novel analgesic," stated David Soergel, M.D., senior vice president of clinical development at Trevena. "In preclinical studies, TRV734 demonstrated an encouraging therapeutic profile, with a potent analgesic effect and a reduced impact on gastrointestinal motility at equianalgesic doses compared to oxycodone. We look forward to further evaluating its potential in a clinical setting."

The main objective of this first-in-human trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of TRV734 in healthy subjects. The potentially efficacious dose range of TRV734 will also be evaluated using pupilometry, a validated biomarker for mu-opioid receptor engagement.

Keywords for this news article include: Pharmaceutical Companies, Analgesics, Trevena Inc, Therapeutics, Pre-Trial Research, Clinical Trials and Studies, Central Nervous System Agents.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools